Cellda Medical have raised over 7 MSEK in capital.

Cellda Medical completed a successful issue of new shares in December 2022 that raised over 7 MSEK in capital.

This will further support the development of a first product of the Cellda® software for the diagnosis of prostate cancer. ”Product development and preparation work continued in 2022 and will now accelerate with the ambition to get Cellda® approved and certified according to IVDR.” says Erik Forsberg, CEO of MM18 Medical AB. Automatic image analysis of tissue samples is key to be able to keep up with the increasing demands and the increasing amount of analyzes pathologists need to carry out. The digital revolution challenges working methods in all parts of society, not least in healthcare. There is a great interest in the use of digital solutions in pathology.

Some new very interesting investors are now shareholders, while existing investors, including UU Invest AB, continued to invest in MM18. ”We are delighted to see these investors recognizing the value of our image analysis technology. Thanks to their support, MM18 can continue its development, contribute to the digital transition in pathology and launch a product that will improve the lives of the patients.” says Sören Nygren, Founder and Chairman of the Board, MM18 Medical AB.

Ready to Transform Cancer Diagnosis?

Join Us in the Future of Healthcare

Discover how Cellda AB is revolutionizing prostate cancer diagnostics. Join the future today.